1. Home
  2. AGIO vs PRG Comparison

AGIO vs PRG Comparison

Compare AGIO & PRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$26.87

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$29.60

Market Cap

1.4B

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
PRG
Founded
2007
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Diversified Commercial Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.4B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
AGIO
PRG
Price
$26.87
$29.60
Analyst Decision
Buy
Buy
Analyst Count
9
6
Target Price
$32.13
$35.00
AVG Volume (30 Days)
2.7M
477.8K
Earning Date
10-30-2025
10-22-2025
Dividend Yield
N/A
1.71%
EPS Growth
N/A
10.59
EPS
N/A
3.96
Revenue
$44,791,000.00
$2,507,179,000.00
Revenue This Year
$28.75
$1.32
Revenue Next Year
$139.45
$0.64
P/E Ratio
N/A
$7.67
Revenue Growth
36.26
3.71
52 Week Low
$22.24
$23.50
52 Week High
$46.00
$48.77

Technical Indicators

Market Signals
Indicator
AGIO
PRG
Relative Strength Index (RSI) 35.66 51.07
Support Level $26.80 $28.88
Resistance Level $28.61 $31.52
Average True Range (ATR) 1.15 1.02
MACD 0.28 0.21
Stochastic Oscillator 16.59 53.24

Price Performance

Historical Comparison
AGIO
PRG

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

Share on Social Networks: